A phase 2 study of Vigil Neuroscience’s iluzanebart has missed its biomarker and efficacy endpoints, prompting the ...

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response ...

Elinzanetant proved effective for managing disruptive vasomotor symptoms in women on endocrine therapy, supporting a Bayer ...

A Kennedy Krieger Institute researcher is playing a role in a major international effort that has yielded a promising ...

A commonly used arthritis medication failed to improve symptoms in people with a specific form of knee osteoarthritis, according to an article published June 2 in JAMA Internal Medicine. In a ...

The cancer drug Enhertu stalled the growth of tumors by well over a year in a group of women with a type of metastatic but ...

By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...

Duke scientists may have discovered a game-changing painkiller. SBI-810 is a new non-opioid drug that offers potent pain ...

As psychedelics gain traction as potential treatments for mental health disorders, an international study stands to improve the rigor and reliability of clinical research.

A new study has found a significant association between the use of GLP-1s such as Ozempic and Wegovy with a higher risk of developing a serious eye condition in patients with diabetes. Here are four t ...

The regulator has set a timeframe of 12th August for its review of the new drug application (NDA ... positive phase 2 data in the Tailwind study – along with Boehringer Ingelheim's cathepsin ...

Conclusion Nearly one-quarter of primary care patients were prescribed antihypertensive drugs by the end of the study period. Most patients with hypertension initiated guideline-recommended first-line ...